Drawing for RAIN

USPTO serial 98544061

RAIN

Reviewed by CopyMark Law Group

Status 653
Filing date
Status date
Registration date
—
Examiner
RIRIE, VERNA BETH
Law office
TMEG LAW OFFICE 104

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with RAIN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kristen Ruisi

Kristen Ruisi Venable LLP151 West 42nd Street, 49th FloorNew York, NY 10036United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of blood-borne pathogens and diseases caused thereby; pharmaceutical preparations for the treatment of viruses, bacteria and other pathogenic organisms and diseases caused therebyACTIVE—
041Educational services, namely, providing a website featuring blogs and non-downloadable publications in the nature of informational articles and guides in the field of health and pharmaceuticals and the treatment of viruses, bacteria and other pathogenic organisms and diseasesACTIVE—
042Providing medical and scientific research information in the field of health and pharmaceuticals on the internet; Research and development of new products for others; Research and development services, namely conducting research focused on the fight against antimicrobial resistance (AMR) and for the treatment of blood-borne pathogens and diseasesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 2, 2026RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Feb 2, 2026GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Feb 2, 2026GNSLLETTER OF SUSPENSION E-MAILED—
Feb 2, 2026CNSLSUSPENSION LETTER WRITTEN—
Dec 10, 2025RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Jun 9, 2025GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Jun 9, 2025GNSLLETTER OF SUSPENSION E-MAILED—
Jun 9, 2025CNSLSUSPENSION LETTER WRITTEN—
Dec 3, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 3, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 3, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 24, 2024GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 24, 2024GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 24, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 9, 2024DOCKASSIGNED TO EXAMINER—
Sep 5, 2024MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Sep 5, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 10, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance